AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” second-quarter 2025 investor ...

The UK’s largest listed companies are turning their heads towards the glimmer of the Nasdaq after growing impatient ...

Pharmaceutical stocks are some of the biggest in the FTSE 100. The sector is threatened by tariffs, but some have posted encouraging results regardless.

Dan Lefkovitz of Morningstar I recently interviewed investor and author Daniel Rasmussen for The Long View podcast, where he ...

The presence of George Osborne at Robey Warshaw, and the payouts to partners following the £146m sale to Evercore, is certain ...

The consolidation is expected to continue as long as the frontline indices trade below the 50-day EMA. Below are some ...

Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects.

Stock markets were mixed on Tuesday as investors started turning their attention from trade deals to a slew of company ...

Two diabetes drugs could become more affordable for Maryland residents, following a study by the Prescription Drug ...